Author(s):
Sreekala. MG, C. Rubina Reichal, Manju. S
Email(s):
rubinareichel@gmail.com
DOI:
10.52711/0974-360X.2024.00015 
Address:
Sreekala. MG1, C. Rubina Reichal2, Manju. S3
1,3Department of Pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore, India.
2Department of Pharmaceutics, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore.
*Corresponding Author
Published In:
Volume - 17,
Issue - 1,
Year - 2024
ABSTRACT:
In this present study, the drug Teneligliptin is selected for the management of Type-2 Diabetes mellitus. The drug-excipient compatibility study results showed that there is no chemical change occur between the drug and the excipients and there was no functional group change observed. Teneligliptin is poorly water-soluble drug and it was fabricated as nanosuspension of Nine formulations by using nano precipitation technique. In this method, nano size particle size of Teneligliptin was obtained by using different type of various proportions of stabilizers along with other ingredient at different stirring speed. For the prepared formulation (F1-F9) the particle size, polydispersibility index and zeta potential were done. Among nine formulations, formulation 8(F8) results revealed that the values are desirable and stable. The total drug content of all the formulation ranges from 81% to 99%, The average particle size of F1 to F9 batches was found to be in the range of 0.211 nm to 0.486 nm The scanning electron microspore study stated that the nano size particles were spherical in shape. Among all the formulations (F8) was optimized which showed maximum highest percentage of drug release at 24 hours. The cumulative percentage of drug release of formulation 8 (F8) increase with the optimum concentration of stabilizers and tween 80. The release rate of optimized formulation 8(F8) was fitted with various release kinetic studies and the selected formulation followed zero order kinetics. The results of stability study was confirmed that the prepared Teneligliptin nanosuspension is stable during the stability study. Thus, it can be concluded that the nanosuspension method was commercially feasible and cost effective.
Cite this article:
Sreekala. MG, C. Rubina Reichal, Manju. S. Formulation and Evaluation of Teneligliptin Nanosuspension. Research Journal of Pharmacy and Technology. 2024; 17(1):96-2. doi: 10.52711/0974-360X.2024.00015
Cite(Electronic):
Sreekala. MG, C. Rubina Reichal, Manju. S. Formulation and Evaluation of Teneligliptin Nanosuspension. Research Journal of Pharmacy and Technology. 2024; 17(1):96-2. doi: 10.52711/0974-360X.2024.00015 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-1-15
REFERENCE:
1. Manish Maladkar, Srividya Sankar, Kushal Kamat, Teneligliptin. Heralding Change in Type 2 Diabetes, Journal of Diabetes Me Eiji Kutoha, Mitsuru Hiratea, Yu Ikenoa, Teneligliptin As an Initial Therapy for Newly Diagnosed. Drug Naive Subjects With Type 2 Diabetes. Journal Clin Med Research. 2014; 6(4): 287-294.
2. Kharkar S, Teneligliptin. A New DPP-4 inhibitor for Type 2 Diabetes.Vidarbha Journal of Internal Medicine. 2016; 21: 34-39
3. Yadav VK and Singh SR. Nanosuspension: a promising drug delivery system. Pharmacopore: An International Research Journal. 2012; 3(5): 217-143.
4. Pataravale BP, Abhijit AD and Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. Journal of Pharmacy and Pharmacology. 2004; 56: 827-840.
5. Bhargavi R: A technical review of nanosuspension. International Journal of Pharmacy and Technology. 2011;3(3):1503-1511.
6. Pooja A. Birade, Vaishali A.Kilor. Formulation and Evaluation of Glimepiride Nanosuspension using Simple High Shera Homogenizer at Lab Scale. IJPPR. 2018; 14(1): 20-29.
7. Smita S. Aher, Sagar T. Malsane, R. B. Saudagar. Nano suspension: An Overview. Asian J. Res. Pharm. Sci. 2017; 7(2): 81-86.
8. Vijay Shinde, P Amsa, S Tamizharasi, D Karthikeyan, T Sivakumar, Abhijit Kosalge. Nano suspensions: A Promising Drug Delivery Strategy. Research J. Pharm. and Tech. 2010; 3(1): 39-44.
9. Pawar Pravin, Yadav Adhikrao, Gharge Varsha. Different Techniques for Preparation of Nano suspension with Reference to its Characterisation and various Applications - A Review. Asian. J. Res. Pharm. Sci. 2018; 8(4): 210-216.
10. Sundar V.D, Divya. P, Sridevi. P, Akhila. K, Dhanaraju M.D. Design, Formulation, and Evaluation of Nanosuspension For Drug Delivery of Celecoxib. Int. J. Pharm. Res. 2019; 11(1); 139-145. 27.
11. Manishaanjane, Shikha Agarwal, Amreen Khan, Formulation and Evaluation of Nanosuspension of Valsartan, Int. J. Curr. Pharm. Res. 2018; 10(2): 63-74.
12. Nehal Daebis et al. Formulation and characterization of itraconazole oral nanosuspension. Dev Drug Cli Tri. 1(1):102.
13. Witika BA, Smith VJ, Walker RB. Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions. Pharmaceutics. 2020; 12(4): 367-379. https://doi.org/10.3390/pharmaceutics12040367.
14. Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Delivery and Translational Research. 2021; 11(3): 748-787. https://doi.org/10.1007/s13346-020-00818-0.
15. Rajesh B Nawale, Uday A Deokate, Sandhana R Shahi, Pradeep M, Lokhande. Formulation and Characterization of Efavirenz Nanosuspension by QbD approach. Research Journal of Pharmacy and Technology. 2017; 10(9): 2960-2972. https://doi.org/10.5958/0974-360X.2017.00525.X
16. Verma S, Gokhale R, Burgess DJ. Pharmaceutical Nanotechnology A Comparative Study of Top-down and Bottom-up Approaches for the Preparation of Micro / Nanosuspensions. 2009; 380:216- 222. https://doi.org/10.1016/j.ijpharm.2009.07.005
17. Yerikala Ramesh, Ballem Sarayu, Guduru Hari Chandana, Obili Neelima, Shaik Sana. Formulation and Evaluation of Lamivudine Nanosuspension. Journal of Drug Delivery & Therapeutics. 2021; 11(4-S): 71-77.
18. C. Rubina Reichal, Christa Roshan Pius, S. Manju, M. Shobana. Formulation and Characterization of Gliclazide Nanosuspension. Research J. Pharm. and Tech. 2021; 14(2):779-786. DOI: 10.5958/0974-360X.2021.00136.0.
19. Suvarna S. Vadje, Rajendra K. Surawase, Santosh S. Surana. Formulation and Evaluation of Nanosuspension Drug Delivery System of Furosemide Produced by Nanoprecipitation Method Int. J. Pharm. Sci. Rev. Res. 2020; 65(2): 50-55.
20. Nita Yadav, Anju Goya. Method development and validation of Teneligliptin in pharmaceutical dosage form by UV spectrophotometric methods. International Journal of Pharmaceutical Chemistry and Analysis. 2017; 4(3): 54-58, DOI:10.18231/2394-2797.2017.0014
21. Shailesh V. Luhar, Kamna R. Pandya, G K. Jani, Sachin B. Narkhed Simultaneous Estimation of Teneligliptin Hydrobromide Hydrate and its Degradation Product by RP-HPLC Method. Journal of Pharmceutical Science and Bioscientific Research, 2016; 6(3): 254-261.
22. Sohan S. Chitlange, Diptee G. Rawat, Sneha Chandani. Estimation of anti-diabetic teneligliptin hydrobromide hydrate by rp-hplc and derivative spectroscopic method Indo American Journal of Pharmaceutical Research, 2016; 6(7): 6144-6153.
23. Amit M. Sonawane, Kiran K. Dhokale, Varsha A. Randhe. A simple UV- spectrophotometric method development and validation of teneligliptin in tablet dosage form. Indo American Journal of Pharmaceutical Research. 2016; 6(4): 5219-5224.
24. Narkkhede NA, Kumar TNV, Vidyadhara S, Sai YS, Lakshmi MR. Method development, Validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy. J Anal Sci Technol. 2016; 7: 18.
25. Bodhle Priyanka Raju, Satish V Shirolkar. Formulation and Evaluation of Teneligliptine Pellet. International Journal of Drug Delivery Technology. 2019; 9(1); 51-57 doi: 10.25258/ijddt.9.1.9.
26. Chotai et al. Formulation and Evaluation of Nanosuspension Drug Delivery System of Etoricoxib. Pharma Science Monitor. 2015; 6(1): 10-27.
27. Raihanul F, Sharif Md, Alok KP, Mohammad SK, et al. In vitro Release Kinetic Study of Gliclazide from Methocel K100MCR and Methocel K100LVCR, Matrix Tablets. Int J Pharm Tech Res. 2012; 4(2): 883-888.
28. Korsmeyer, Gurny R, Doelker E, Buri P, et al. Mechanisms of Solute Release from Porous Hydrophilic Polymers. Int J Pharm. 1983; 15: 25-35.